

2019-nCoV Spike protein RBD (E484Q)

Catalog No: C19SD-G231CH

Viruses harboring mutations in the spike protein have reduced susceptibility to both monoclonal antibodies and convalescent plasma. As these new variants displace the first-wave virus, it is pivotal to evaluate their transmissibility, virulence and their possible tendency to escape antibody neutralization.

- Expressed in CHO cells using a C-terminal his tag.
- RBD E484Q mutation has been detected in the South African (B.1.351), Brazilian (P.1), and NY variants (B.1.526).
- Lineage B.1.617, also known as the Indian variant carries E484Q mutation in combination with L452R.

Product Features



90% Purity




Fully Functional
Protein



Expressed in
CHO cells



QA/QC
Tested



Competitors



Target Customers



Covid19 researchers
working on E484Q
neutralization



Scientists testing
Covid19 variants



Biopharma
companies



Diagnostic kits
R&D